---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-029378"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T06:07:58.720283+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Innoviva Q4 net income $61.5M, royalty revenue $69.6M; product sales up 35% YoY

## Summary
- Q4 net income $61.5M ($0.97 EPS) vs $68.3M loss in Q4 2022; full-year net income $179.7M.
- Q4 GSK royalty revenue $69.6M; net product sales $19.7M (+35% YoY) driven by GIAPREZA ($13.1M) and XERAVA ($5.2M).
- Repurchased 1.1M shares for $15.4M in Q4; full-year repurchases $76.5M; $15M authorization remaining.
- XACDURO approved for HABP/VABP; zoliflodacin met Phase 3 primary endpoint; NDA filing within 12 months.
- Cash and receivables >$275M; strategic assets valued at $561M; invested $5M in Gate Neurosciences.

## SEC filing metadata
- accession: 0001104659-24-029378
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000110465924029378/0001104659-24-029378-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000110465924029378/tm247467d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-029378
- JSON: https://secwatch.observer/filing/0001104659-24-029378.json
- Plain text: https://secwatch.observer/filing/0001104659-24-029378.txt

## Key facts
- Earnings Releases
  Innoviva, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income net income was $61.5 million, or $0.97 basic per share.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Net income: net income was $61.5 million, or $0.97 basic per share
  - Result: reported results
  source text: On February 29, 2024, Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1080014/000110465924029378/0001104659-24-029378-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.